tbuckley/cabot-search huggingface dataset:
SAT0250 Cost of health care in dutch fibromyalgia patients: a retrospective survey
Authors: TR Zijlstra, JJ Rasker, MA van de Laar, HJ Bernelot Moens
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> <h3>Objectives</h3> To estimate the cost of health care in primary fibromyalgia (FM) patients. <h3>Methods</h3> All persons diagnosed as FM in our rheumatology outpatient clinic during the last 3 years and members of the Dutch FM patient association were invited to participate in a study on the social impact of FM. Only persons fulfilling ACR criteria for FM, aged 18–65, and without significant co-morbidity, were included. They completed a questionnaire on the impact of FM in the preceding six months, with questions regarding the type, amount and cost of health care they had received during this period. Mean cost was estimated using standardised prizes in Dutch guilders and transformed to Euros (?). <h3>Results</h3> The questionnaire was completed by 135 persons (mean age 47 years, standard deviation SD 8.6, 128 females). They reported a mean number of 4 visits (SD 3) to their general practitioner for the six month period, (two of these (SD 2) because of FM) and a mean of 2 visits (SD 2) to medical specialists and 13 visits (SD 15) to health professionals, mainly physiotherapists. One person visited a rehabilitation centre for 1 day per week, 8 patients were admitted to hospital for not-FM related reasons. The mean cost of analgesics, anti-depressants and tranquillisers per six months was ? 52. Apart from this, a reported average of ? 17 was paid for homeopathic and other alternative drugs. Forty-two persons visited complementary or alternative therapists, at a mean cost of ? 61 per person. Participants reported an average of 10.8 (SD 31.5) hours of reimbursed domestic help. A mean sum of ? 159 was paid for devices and adaptations. The table shows estimated costs. Overall health care costs per person per year were ? 2333. <h3>Discussion</h3> Since this is not a population-based study, we should consider the possibility of selection bias. On the other hand, in our retrospective study design recall bias may have caused an underestimation of true costs. Although exact data are lacking, we expect that cost of health professionals, complementary and alternative medicine and domestic help are mainly FM-related. The estimated cost of health care for Dutch women aged 45–49 year is ? 1470 per person per year. <h3>Conclusion</h3> The cost of health care in Dutch FM patients is approximately 60% higher than in the age-related general population. Therefore FM is not only a problem in terms of quality of life, but also in terms of health care economics.
COVID-19: guidance on palliative care from a European Respiratory Society international task force
Authors: Daisy J.A. Janssen, Magnus Ekström, David C. Currow, Miriam J. Johnson, Matthew Maddocks, Anita K. Simonds, Thomy Tonia, Kristoffer Marsaa
Journal: European Respiratory Journal (2020)

Background Many people are dying from coronavirus disease 2019 (COVID-19), but consensus guidance on palliative care in COVID-19 is lacking. This new life-threatening disease has put healthcare systems under pressure, with the increased need of palliative care provided to many patients by clinicians who have limited prior experience in this field. Therefore, we aimed to make consensus recommendations for palliative care for patients with COVID-19 using the Convergence of Opinion on Recommendations and Evidence (CORE) process. Methods We invited 90 international experts to complete an online survey including stating their agreement, or not, with 14 potential recommendations. At least 70% agreement on directionality was needed to provide consensus recommendations. If consensus was not achieved on the first round, a second round was conducted. Results 68 (75.6%) experts responded in the first round. Most participants were experts in palliative care, respiratory medicine or critical care medicine. In the first round, consensus was achieved on 13 recommendations based upon indirect evidence and clinical experience. In the second round, 58 (85.3%) out of 68 of the first-round experts responded, resulting in consensus for the 14th recommendation. Conclusion This multi-national task force provides consensus recommendations for palliative care for patients with COVID-19 concerning: advance care planning; (pharmacological) palliative treatment of breathlessness; clinician–patient communication; remote clinician–family communication; palliative care involvement in patients with serious COVID-19; spiritual care; psychosocial care; and bereavement care. Future studies are needed to generate empirical evidence for these recommendations.
Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020
Authors: Fiona P. Havers, Carrie Reed, Travis Lim, Joel M. Montgomery, John D. Klena, Aron J. Hall, Alicia M. Fry, Deborah L. Cannon, Cheng-Feng Chiang, Aridth Gibbons, Inna Krapiunaya, Maria Morales-Betoulle, Katherine Roguski, Mohammad Ata Ur Rasheed, Brandi Freeman, Sandra Lester, Lisa Mills, Darin S. Carroll, S. Michele Owen, Jeffrey A. Johnson, Vera Semenova, Carina Blackmore, Debra Blog, Shua J. Chai, Angela Dunn, Julie Hand, Seema Jain, Scott Lindquist, Ruth Lynfield, Scott Pritchard, Theresa Sokol, Lynn Sosa, George Turabelidze, Sharon M. Watkins, John Wiesman, Randall W. Williams, Stephanie Yendell, Jarad Schiffer, Natalie J. Thornburg
Journal: JAMA Internal Medicine (2020)

Reported cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection likely underestimate the prevalence of infection in affected communities. Large-scale seroprevalence studies provide better estimates of the proportion of the population previously infected.
Hospital Investments in Housing—Banner of Change or Red Flag?
Authors: Suhas Gondi, Adam L. Beckman, J. Michael McWilliams
Journal: JAMA Internal Medicine (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
The monoclonal antibody 7.16.4 sequenced with cyclophosphamide-modulated vaccination maximizes tumor immunity and tumor-free survival in tumor-bearing tolerant neu-N mice
Authors: James Leatherman, Justin Asquith, John Ullman, Peter Kim, Matthew Emmett, Joy Levi, Elizabeth Manning, Elizabeth Jaffee, Leisha Emens
Journal: Cancer Research (2008)

4995  HER-2/neu (HER-2) is overexpressed in up to 25% of human breast cancers, and portends a poor prognosis. HER-2 is also a target of the antitumor immune response in breast cancer patients. Notably, the humanized monoclonal antibody Trastuzumab can result in the clinical remission of treatment-refractory metastatic breast tumors that overexpress HER-2, and improves clinical outcomes for early breast cancer as well. Neu-N mice transgenic for the rat protooncogene neu spontaneously develop mammary tumors, and are profoundly immune-tolerant to HER-2. We previously showed that a low dose of Cyclophosphamide (CY) given one day prior to vaccination can eliminate the negative influence of regulatory T cells in neu-N mice, enabling the cure of up to 25% of tumor-bearing mice. We also showed that HER-2-specific monoclonal antibodies combined with vaccine could augment HER-2-specific CD8+ T cell immunity and tumor-free survival in neu-N mice. We hypothesized that both abrogating the influence of regulatory T cells with CY, and augmenting antigen processing and presentation with the HER-2-specific MAb would maximize the tumor rejection response in tumor-bearing animals. As a model for clinical translation, we used the Trastuzumab-like murine MAb 7.16.4. The administration a low dose of CY with weekly 7.16.4 MAb to neu-N mice with pre-established tumors resulted in tumor-free survival rates of about 10% at 50 days after tumor challenge. Treating tumor-bearing neu-N mice with HER-2+, GM-CSF-secreting vaccination added to CY + 7.16.4 MAb therapy increased the tumor-free survival rate to 55%. The effect was associated with an increase in HER-2-specific CD8+ T cells, anti-tumor antibodies, and tumor cell apoptosis. These data support the testing of CY-modulated vaccination in the setting of weekly Trastuzumab therapy in patients with advanced HER-2+ breast cancers.
The Use of FDG PET Parametric Imaging in the Diagnosis of Olivopontocerebellar Atrophy
Authors: Nassier Harfouch, Mark Finkelstein, Swati Sathe, Mark Raden, Arnold I. Brenner
Journal: Clinical Nuclear Medicine (2020)

Abstract Olivopontocerebellar atrophy is a rare neurodegenerative syndrome associated with 2 distinct disorders: multiple system atrophy and spinocerebellar ataxia. We present a case involving a 66-year-old man with adult-onset progressing cerebellar signs reflective of a cerebellar syndrome with no significant family history and unremarkable genetic testing for spinocerebellar ataxia. This case was found to be most consistent with sporadic olivopontocerebellar atrophy, which falls under the multiple system atrophy category. This diagnosis can be made using 18 F-FDG PET/CT scanning and with MRI in some cases. However, in this case, relatively new PET/CT quantification and parametric imaging software was used for analysis, CortexID Suite.
AB0164 ACTIVITIES OF THE OXIDATIVE-RELATED ENZYMES IN SYSTEMIC SCLEROSIS
Authors: E. Mozgovaya, I. Zborovskaya, S. Bedina, A. Trofimenko, M. Mamus, E. Tikhomirova, S. Spitsina
Journal: Annals of the Rheumatic Diseases (2020)

Background: The oxidative-related enzymes are involved in the pathogenesis of various stages of systemic sclerosis (SSc). SSc is a chronic autoimmune disorder that is intimately associated with vascular damage and therefore with chronic perfusion/reperfusion and oxidative organ injury. Mesenchymal cell activation in SSc is now also considered to be mediated primarily through oxidative burst. Regulation of oxidative stress by specific enzymes including several purine metabolism enzymes is likely to play an important role in SSc progression. Objectives: to characterize interrelationships among circulating xanthine oxidase (XO), xanthine dehydrogenase (XDH), superoxide dismutase (SOD) activities and SSc activity. Methods: The study was performed according to bioethical standards. 51 patients with verified SSc and 30 healthy controls were included in the study. The diagnosis was verified according to ACR/EULAR 2013 criteria. We assessed SSc activity in compliance with the original activity scale that is commonly used in Russia [Guseva N.G., 1993] and by the 2001 European Scleroderma Study Group Activity Index. XO (EC 1.17.3.2), XDH (EC 1.17.1.4), and SOD (EC 1.15.1.1) plasma activities were measured using spectrophotometric techniques as previously described [Dubinina E.E., 1986; Karpova O.V., 2006]. Results are expressed as mean±SD. The Mann-Whitney U test and Spearman’s correlation coefficient were used for statistical analysis. Results: Mean age of patients was 42.8±1.3 years, mean SSc duration was 7.9±0.7 years. Mean enzymatic activities in normal controls were 3.43±0.56 nmol/ml min (for XO), 5.19±0.71 nmol/ml min (for XDH), and 5.40±1.03 units (for SOD). The respective enzymatic activities in SSc group were 3.91±0.62 nmol/ml min, 7.10±0.71 nmol/ml min, and 7.10±2.19 units. All these mean activities were significantly higher in SSc patients comparing to healthy individuals (p&lt;0.001). XO and XDH activities positively correlated with SSc activity (r=0.499, p&lt;0.001, and r=0.741, p&lt;0.001, respectively). The opposite but weaker trend was observed for SOD activity and SSc disease activity (r=-0.190, p=0.188). Conclusion: SSc is characterized by an increase in the intensity of oxidative and antioxidant processes, more pronounced in high disease activity. A close relationship between function of prooxidant/antioxidant enzymes and some of the key SSc pathogenetic mechanisms, especially vascular disease and fibroblast activation, is widely considered. Overall increase of oxidative stress in patients with higher disease activity, as well as depletion of antioxidant capacity can be also linked with disturbance of purine metabolism through XO and XDH modulation. Pathogenetic influence of this imbalance can also be mediated through initial phase of neutrophil extracellular traps (NETs) formation, an eventual source of nucleoprotein containing autoepitopes. Disclosure of Interests: None declared
Differential Effects on Ocular Biometrics by 0.05%, 0.025%, and 0.01% Atropine
Authors: Fen Fen Li, Ka Wai Kam, Yuzhou Zhang, Shu Min Tang, Alvin L. Young, Li Jia Chen, Clement C. Tham, Chi Pui Pang, Jason C. Yam
Journal: Ophthalmology (2020)
Mitochondria as a target in cancer treatment
Authors: Yu'e Liu, Yufeng Shi
Journal: MedComm (2020)

Abstract Mitochondria are biosynthetic, bioenergetic, and signaling organelles existing in almost all eukaryotic cells, and their dysregulated function has been proved to be essential for tumorigenesis, tumor development, and tumor metastasis. In this short review, first, we briefly summarize the historic misunderstanding of mitochondria in tumors, and then come up with a current view that mitochondria play a pivotal role in tumor cells; second, we review how tumor cells rewind mitochondrial function for their oncogenic purpose via known or unknown mechanisms by key oncogenes or tumor suppressors; third, we go through reagents and strategies currently available targeting mitochondria when treating tumors. Recently, merging data suggest that slow cycling cancer cells/cancer stem cells have distinctive mitochondrial metabolism comparing to bulk tumor cells and mitochondria inhibitors seem to be promising to target them, which are resistant to traditional radio and chemotherapies. We thus discuss role of mitochondria in these cancer stem cells and summarize mitochondria as a target from different aspects.
Characteristics of nonmelanoma skin cancer in children without identifiable risk factors
Authors: Connie S. Zhong, Carrie C. Coughlin, Elena B. Hawryluk, Kristen Hook, Stephen R. Humphrey, Lacey Kruse, Leslie Lawley, Pei-Chi Kao, Wendy B. London, Ashfaq A. Marghoob, Thuy L. Phung, Elena Pope, Pedram Gerami, Birgitta Schmidt, Eman Bahrani, Diana Bartenstein, Meera Brahmbhatt, Lily Chen, Ellen Haddock, Danny Mansour, Julie Nguyen, Tom Raisanen, Sarah Robinson, Tova Rogers, Gary Tran, Kate Travis, Zachary Wolner, Lawrence F. Eichenfield, Jennifer T. Huang
Journal: Journal of the American Academy of Dermatology (2020)
Pulsed radiation therapy for the treatment of newly diagnosed glioblastoma
Authors: Muayad F Almahariq, Thomas J Quinn, Jessica D Arden, P T Roskos, George D Wilson, Brian Marples, Inga S Grills, Peter Y Chen, Daniel J Krauss, Prakash Chinnaiyan, Joshua T Dilworth
Journal: Neuro-Oncology (2020)

Abstract Background Pulsed radiation therapy (PRT) has shown effective tumor control and superior normal-tissue sparing ability compared with standard radiotherapy (SRT) in preclinical models and retrospective clinical series. This is the first prospective trial to investigate PRT in the treatment of patients with newly diagnosed glioblastoma (GBM). Methods This is a single-arm, prospective study. Patients with newly diagnosed GBM underwent surgery, followed by 60 Gy of PRT with concurrent temozolomide (TMZ). Each day, a 2-Gy fraction was divided into ten 0.2-Gy pulses, separated by 3-minute intervals. Patients received maintenance TMZ. Neurocognitive function (NCF) and quality of life (QoL) were monitored for 2 years using the Hopkins Verbal Learning Test‒Revised and the European Organisation for Research and Treatment of Cancer QLQ-C30 QoL questionnaire. Change in NCF was evaluated based on a minimal clinically important difference (MCID) threshold of 0.5 standard deviation. Results Twenty patients were enrolled with a median follow-up of 21 months. Median age was 60 years. Forty percent underwent subtotal resection, and 60% underwent gross total resection. One patient had an isocitrate dehydrogenase (IDH)–mutated tumor. Median progression-free survival (PFS) and overall survival (OS) were 10.7 and 20.9 months, respectively. In a post-hoc comparison, median OS for the prospective cohort was longer, compared with a matched cohort receiving SRT (20.9 vs 14 mo, P = 0.042). There was no decline in QoL, and changes in NCF scores did not meet the threshold of an MCID. Conclusions Treatment of newly diagnosed GBM with PRT is feasible and produces promising effectiveness while maintaining neurocognitive function and QoL. Validation of our results in a larger prospective trial warrants consideration.
Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group
Authors: Mehmet Kemal Samur, Anil Aktas Samur, Mariateresa Fulciniti, Raphael Szalat, Tessa Han, Masood Shammas, Paul Richardson, Florence Magrangeas, Stephane Minvielle, Jill Corre, Philippe Moreau, Anjan Thakurta, Kenneth C. Anderson, Giovanni Parmigiani, Hervé Avet-Loiseau, Nikhil C. Munshi
Journal: Journal of Clinical Oncology (2020)

PURPOSE Multiple myeloma (MM) is accompanied by heterogeneous somatic alterations. The overall goal of this study was to describe the genomic landscape of myeloma using deep whole-genome sequencing (WGS) and develop a model that identifies patients with long survival. METHODS We analyzed deep WGS data from 183 newly diagnosed patients with MM treated with lenalidomide, bortezomib, and dexamethasone (RVD) alone or RVD + autologous stem cell transplant (ASCT) in the IFM/DFCI 2009 study (ClinicalTrials.gov identifier: NCT01191060 ). We integrated genomic markers with clinical data. RESULTS We report significant variability in mutational load and processes within MM subgroups. The timeline of observed activation of mutational processes provides the basis for 2 distinct models of acquisition of mutational changes detected at the time of diagnosis of myeloma. Virtually all MM subgroups have activated DNA repair–associated signature as a prominent late mutational process, whereas APOBEC signature targeting C&gt;G is activated in the intermediate phase of disease progression in high-risk MM. Importantly, we identify a genomically defined MM subgroup (17% of newly diagnosed patients) with low DNA damage (low genomic scar score with chromosome 9 gain) and a superior outcome (100% overall survival at 69 months), which was validated in a large independent cohort. This subgroup allowed us to distinguish patients with low- and high-risk hyperdiploid MM and identify patients with prolongation of progression-free survival. Genomic characteristics of this subgroup included lower mutational load with significant contribution from age-related mutations as well as frequent NRAS mutation. Surprisingly, their overall survival was independent of International Staging System and minimal residual disease status. CONCLUSION This is a comprehensive study identifying genomic markers of a good-risk group with prolonged survival. Identification of this patient subgroup will affect future therapeutic algorithms and research planning.
Abstract 15214: Hematopoietic Stem-Cell Transplantation Improves Right Ventricular Strain in Patients With Systemic Sclerosis
Authors: Emily J Li, William Schultz, Stanley Swat, Arif Jivan, Sanjiv J Shah, Richard Burt, Benjamin H Freed
Journal: Circulation (2019)

Introduction: Systemic sclerosis (SSc) is characterized by multi-organ fibrosis. Cardiac involvement in SSc often portends a worse prognosis. Recent studies show the benefit of hematopoietic stem-c...
Evaluating the Efficacy, Safety, and Dose Dependent Activities of Entospletinib in Patients with Chronic Lymphocytic Leukemia
Authors: Jeffrey P. Sharman, Kathryn S. Kolibaba, Jose Azar, Rama Balaraman, Roger M. Lyons, Mitchell R. Smith, Esteban Abella-Dominicis, Wei Ye, Wen Shi, Thomas Giever, Andres Forero-Torres
Journal: Blood (2017)
Formation of an intersectoral network to support trans survivors of sexual assault: A survey of health and community organizations
Authors: Janice Du Mont, Sarah Daisy Kosa, Shilini Hemalal, Lee Cameron, Sheila Macdonald
Journal: International Journal of Transgender Health (2020)

To address the growing international recognition of the inequities faced by transgender (trans) persons and the lack of services that attend to the specific concerns of trans sexual assault survivors, we undertook the development of an intersectoral network of hospital-based violence treatment centers and trans-positive community organizations to enhance available supports.To examine anticipated involvement of organizations in the network and determine network activities, deliverables, and values.We developed a survey with guidance from an advisory group of trans community members and their allies. Items on the survey related to network activities, deliverables, and values, which were also informed by key insights from earlier network planning meetings, were rated on a 5-point Likert scale for their importance (1 = not important at all, 5 = very important).Sixty-four out of 93 organizations invited responded to the survey, giving a response rate of 69%. The highest prioritized network activities were: improve access to support services for trans survivors, educate trans survivors on their rights/what to expect when seeking supports and information on organizations, provide ongoing education/training for service providers on trans-affirming care, and inform guidelines on appropriate and sensitive standards of care/better practices for trans survivors (means = 4.6). The highest prioritized deliverables were: provision of standardized sensitivity training on violence against trans persons for professionals and development of an online directory/resource list of trans-affirming service providers and organizations that is continuously updated (means = 4.5). Trauma- and violence-informed and trans-guided were the most highly rated values (means = 4.8).These findings have implications for healthcare and community leaders seeking to collaborate across sectors to address the inequities faced by trans persons experiencing sexual assault.
Long-Term Outcomes of Implantable Cardioverter-Defibrillator Therapy in the SCD-HeFT
Authors: Jeanne E. Poole, Brian Olshansky, Daniel B. Mark, Jill Anderson, George Johnson, Anne S. Hellkamp, Linda Davidson-Ray, Daniel P. Fishbein, Robin E. Boineau, Kevin J. Anstrom, Per G. Reinhall, Douglas L. Packer, Kerry L. Lee, Gust H. Bardy
Journal: Journal of the American College of Cardiology (2020)